Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort

Conen, Katrin; Hagmann, Raphael; Hess, Viviane; Zippelius, Alfred; Rothschild, Sacha I.

doi:10.7150/jca.16211



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2016; 7(14):2110-2116. doi:10.7150/jca.16211 This issue Cite

Research Paper

Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort

Katrin Conen^1✉, Raphael Hagmann¹, Viviane Hess¹, Alfred Zippelius^1,2, Sacha I. Rothschild^1,2

1. Department of Internal Medicine, Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
2. Lung Tumor Center, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland

Citation:

Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. J Cancer 2016; 7(14):2110-2116. doi:10.7150/jca.16211. https://www.jcancer.org/v07p2110.htm

Other styles

Abstract

Objectives: Bone metastases (BM) and skeletal-related events (SREs) are frequent complications in patients with lung cancer. Whereas in non-small-cell lung cancer (NSCLC) incidence, prognostic impact, and risk factors are well established, there is only little knowledge in patients with small cell lung cancer (SCLC). We retrospectively evaluated the incidence of BM, SRE and their treatment in a SCLC patient cohort treated at our hospital. We further assessed the role of Lactate Dehydrogenase (LDH), a possible predictor of BM development in SCLC patients.

Materials and Methods: We retrospectively analyzed patients with the diagnosis of SCLC for BM, SRE, overall treatment patterns, outcome and established prognostic parameters by record review. The prognostic role of LDH was tested using univariate longitudinal regression analysis.

Results: We identified 92 consecutive patients with SCLC diagnosed between 2000 and 2010 at our institution. Overall, 36.9% presented with BM at first diagnosis. Median time to BM from first diagnosis was 14.8 months (range) in limited disease (LD) and 0.9 months (range) in extensive disease (ED). The overall incidence of SRE was 18.4%. Only 19.6% of patients with BM were initially treated with bisphosphonates.

Conclusions: Elevated LDH, as well as age ≥75 years were independent predictors for BM development in SCLC patients. Although SREs are relevant complications in SCLC, early antiresorptive treatment of BM to reduce the risk of SREs was rare. LDH served as a predictive factor for BM development in our SCLC cohort and therefore should be taken into account in future randomized controlled trials.

Keywords: Bone metastases, Skeletal-related event, Small Cell Lung Cancer, LDH, Predictive factor

Citation styles

APA

Conen, K., Hagmann, R., Hess, V., Zippelius, A., Rothschild, S.I. (2016). Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. Journal of Cancer, 7(14), 2110-2116. https://doi.org/10.7150/jca.16211.

ACS

Conen, K.; Hagmann, R.; Hess, V.; Zippelius, A.; Rothschild, S.I. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. J. Cancer 2016, 7 (14), 2110-2116. DOI: 10.7150/jca.16211.

NLM

CSE

Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI. 2016. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. J Cancer. 7(14):2110-2116.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.